U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06795373) titled 'Ritlecitinib (PF-06651600) in Participants with Chronic Spontaneous Urticaria' on Jan. 22.
Brief Summary: The purpose of this research study is to see if a drug called ritlecitinib is safe and effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration (FDA) to treat another condition, but it is not approved for treating CSU. Participation is expected to last 20 weeks and include 7 clinic visits. This study will involve physical examinations, blood tests, looking at and taking pictures of participant's skin and hives, option...